Learning Objectives: 

  • Describing the risk spectrum across the spectrum of CAD
  • The role of platelets across the spectrum of CAD
  • The role of antiplatelets in patients with CAD at high risk of CV events, ACS and patients with a history of MI.

This content is developed exclusively by or on behalf of the industry sponsor; it is not reviewed or associated with Pri-Med and Pri-Med does not endorse or sanction any third-party content. 


Faculty

Ted Okerson, MD

Biopharmaceuticals, US Medical | CVMD
AstraZeneca Pharmaceuticals, LP 

Industry Sponsor

AstraZeneca


Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.